Journal of Nutrition and Health

The Korean Nutrition Society (한국영양학회)
권호 표지
DOI QR코드

DOI QR Code

Correlation of advanced glycation end products and heme oxygenase-1 in Korean diabetic patients

제2형 당뇨병 환자에서 최종당화산물과 heme oxygenase-1의 상관성

  • Choi, Ha-Neul (Department of Food and Nutrition, Changwon National University) ;
  • Koo, Da-Hye (Department of Food and Nutrition, Changwon National University) ;
  • Yim, Jung-Eun (Department of Food and Nutrition, Changwon National University)
  • Received : 2022.03.15
  • Accepted : 2022.05.09
  • Published : 2022.06.30
Download PDF
⟨ Previous Next ⟩

Abstract

Purpose: Hyperglycemia accelerates the formation of advanced glycation end products (AGEs), a group of compounds formed via non-enzymatic glycation/glycoxidation. Type 2 diabetes mellitus (T2DM) is related to oxidative stress, resulting in some overgeneration of AGEs. The accumulation of AGEs in T2DM patients leads to increased inflammation, DNA damage, tissue damage, progression of diabetic microvascular disease, and nephropathy. Heme oxygenase-1 (HO-1) is an intracellular enzyme that catalyzes the oxidation of heme. Expression of HO-1 in the endothelium and in muscle monocytes/macrophages was upregulated upon exposure to reactive oxygen species or oxidized low-density lipoprotein. Cells activated by oxidative stress are reported to release HO-1 in the serum. In the current study, we discuss the oxidative status according to the level of AGEs and the association of HO-1 with AGEs or urinary DNA damage marker in type 2 diabetic Korean patients. Methods: This study enrolled 36 diabetic patients. Subjects were classified into two groups by serum AGEs level (Low AGEs group: < 0.85 ng/mL serum AGEs; High AGEs group: ≥ 0.85 ng/mL serum AGEs). Body composition was measured using bioelectrical impedance analysis. Blood and urinary parameters were measured using commercial kits. Results: No significant differences were observed in the general characteristics and body composition between the two groups. Serum HO-1 concentration was significantly higher in the High AGEs group than in the Low AGEs group. After adjustment of age and gender, a correlation was performed to assess the association between serum HO-1 and serum AGEs or urinary 8-hydroxy-2'-deoxyguanosine (8-OHdG). Our results indicate that serum HO-1 is positively correlated with serum AGEs and urinary 8-OHdG. Conclusion: Taken together, our results indicate that in diabetes patients, a high level of HO-1 is associated with a high concentration of AGEs and 8-OHdG, probably reflecting a protective response against oxidative stress.

본 연구는 한국에서 최초로 시행되는 연구로서, 성인 제2형 당뇨환자에서 혈청 AGEs의 농도에 따라 두 군으로 나눈 뒤 신체계측 및 체조성, 영양소 섭취량, 생화학적 지표를 비교 분석한 연구이다. Low AGEs group과 High AGEs group의 평균 AGEs는 각각 0.4 ± 0.2, 3.4 ± 1.7 ng/mL로 나타났다. 항산화 효소인 HO-1은 High AGEs group이 Low AGEs group에 비해 유의적으로 높게 나타났다. 또한, 전체 연구참여자를 대상으로 연령과 성별을 보정한 후 상관관계를 분석한 결과, 혈청 HO-1 농도와 혈청 AGEs 농도 및 소변 8-OHdG 농도는 양의 상관관계를 가지는 것으로 나타났다. 본 연구를 통해 혈청 HO-1은 당뇨환자 특이적 지표인 AGEs와 더불어 DNA 손상 지표에도 예민하게 반응하는 것을 확인하였으며, 추후 한국 당뇨환자의 산화적 스트레스와 합병증 연구의 근거자료로 널리 사용될 수 있을 것으로 사료된다.

Keywords

Acknowledgement

This research was supported by Changwon National University in 2021~2022.

References

  1. Jung CH, Son JW, Kang S, Kim WJ, Kim HS, Kim HS, et al. Diabetes fact sheets in Korea, 2020: an appraisal of current status. Diabetes Metab J 2021; 45(1): 1-10. https://doi.org/10.4093/dmj.2020.0254
  2. Giri B, Dey S, Das T, Sarkar M, Banerjee J, Dash SK. Chronic hyperglycemia mediated physiological alteration and metabolic distortion leads to organ dysfunction, infection, cancer progression and other pathophysiological consequences: an update on glucose toxicity. Biomed Pharmacother 2018; 107: 306-328. https://doi.org/10.1016/j.biopha.2018.07.157
  3. Giacco F, Brownlee M. Oxidative stress and diabetic complications. Circ Res 2010; 107(9): 1058-1070. https://doi.org/10.1161/CIRCRESAHA.110.223545
  4. Singh VP, Bali A, Singh N, Jaggi AS. Advanced glycation end products and diabetic complications. Korean J Physiol Pharmacol 2014; 18(1): 1-14. https://doi.org/10.4196/kjpp.2014.18.1.1
  5. Li J, Shangguan H, Chen X, Ye X, Zhong B, Chen P, et al. Advanced glycation end product levels were correlated with inflammation and carotid atherosclerosis in type 2 diabetes patients. Open Life Sci 2020; 15(1): 364-372. https://doi.org/10.1515/biol-2020-0042
  6. Nowotny K, Jung T, Hohn A, Weber D, Grune T. Advanced glycation end products and oxidative stress in type 2 diabetes mellitus. Biomolecules 2015; 5(1): 194-222. https://doi.org/10.3390/biom5010194
  7. Tobon-Velasco JC, Cuevas E, Torres-Ramos MA. Receptor for AGEs (RAGE) as mediator of NF-κB pathway activation in neuroinflammation and oxidative stress. CNS Neurol Disord Drug Targets 2014; 13(9): 1615-1626. https://doi.org/10.2174/1871527313666140806144831
  8. Indyk D, Bronowicka-Szydelko A, Gamian A, Kuzan A. Advanced glycation end products and their receptors in serum of patients with type 2 diabetes. Sci Rep 2021; 11(1): 13264. https://doi.org/10.1038/s41598-021-92630-0
  9. Xu GW, Yao QH, Weng QF, Su BL, Zhang X, Xiong JH. Study of urinary 8-hydroxydeoxyguanosine as a biomarker of oxidative DNA damage in diabetic nephropathy patients. J Pharm Biomed Anal 2004; 36(1): 101-104. https://doi.org/10.1016/j.jpba.2004.04.016
  10. Dong QY, Cui Y, Chen L, Song J, Sun L. Urinary 8-hydroxydeoxyguanosine levels in diabetic retinopathy patients. Eur J Ophthalmol 2008; 18(1): 94-98. https://doi.org/10.1177/112067210801800116
  11. Panchenko MV, Farber HW, Korn JH. Induction of heme oxygenase-1 by hypoxia and free radicals in human dermal fibroblasts. Am J Physiol Cell Physiol 2000; 278(1): C92-C101. https://doi.org/10.1152/ajpcell.2000.278.1.c92
  12. Bao W, Rong S, Zhang M, Yu X, Zhao Y, Xiao X, et al. Plasma heme oxygenase-1 concentration in relation to impaired glucose regulation in a non-diabetic Chinese population. PLoS One 2012; 7(3): e32223. https://doi.org/10.1371/journal.pone.0032223
  13. Bao W, Song F, Li X, Rong S, Yang W, Zhang M, et al. Plasma heme oxygenase-1 concentration is elevated in individuals with type 2 diabetes mellitus. PLoS One 2010; 5(8): e12371. https://doi.org/10.1371/journal.pone.0012371
  14. Rasool M, Malik A, Butt TT, Ashraf MAB, Rasool R, Zahid A, et al. Implications of advanced oxidation protein products (AOPPs), advanced glycation end products (AGEs) and other biomarkers in the development of cardiovascular diseases. Saudi J Biol Sci 2019; 26(2): 334-339. https://doi.org/10.1016/j.sjbs.2018.08.024
  15. Smit AJ, Lutgers HL. The clinical relevance of advanced glycation endproducts (AGE) and recent developments in pharmaceutics to reduce AGE accumulation. Curr Med Chem 2004; 11(20): 2767-2784. https://doi.org/10.2174/0929867043364342
  16. van Waateringe RP, Slagter SN, van Beek AP, van der Klauw MM, van Vliet-Ostaptchouk JV, Graaff R, et al. Skin autofluorescence, a non-invasive biomarker for advanced glycation end products, is associated with the metabolic syndrome and its individual components. Diabetol Metab Syndr 2017; 9(1): 42. https://doi.org/10.1186/s13098-017-0241-1
  17. Choi EY, Kwon HM, Ahn CW, Lee GT, Joung B, Hong BK, et al. Serum levels of advanced glycation end products are associated with in-stent restenosis in diabetic patients. Yonsei Med J 2005; 46(1): 78-85. https://doi.org/10.3349/ymj.2005.46.1.78
  18. Shin HY, Kang HT. Recent trends in the prevalence of underweight, overweight, and obesity in Korean adults: The Korean National Health and Nutrition Examination Survey from 1998 to 2014. J Epidemiol 2017; 27(9): 413-419. https://doi.org/10.1016/j.je.2016.08.014
  19. Smith U. Abdominal obesity: a marker of ectopic fat accumulation. J Clin Invest 2015; 125(5): 1790-1792. https://doi.org/10.1172/JCI81507
  20. Lim S, Meigs JB. Links between ectopic fat and vascular disease in humans. Arterioscler Thromb Vasc Biol 2014; 34(9): 1820-1826. https://doi.org/10.1161/ATVBAHA.114.303035
  21. Jeon J, Jung KJ, Jee SH. Waist circumference trajectories and risk of type 2 diabetes mellitus in Korean population: the Korean Genome and Epidemiology Study (KoGES). BMC Public Health 2019; 19(1): 741. https://doi.org/10.1186/s12889-019-7077-6
  22. Kim TJ, Kim HJ, Kim YB, Lee JY, Lee HS, Hong JH, et al. Comparison of surrogate markers as measures of uncomplicated insulin resistance in Korean adults. Korean J Fam Med 2016; 37(3): 188-196. https://doi.org/10.4082/kjfm.2016.37.3.188
  23. Rhee EJ, Kim HC, Kim JH, Lee EY, Kim BJ, Kim EM, et al. 2018 Guidelines for the management of dyslipidemia in Korea. Korean J Intern Med 2019; 34(5): 1171. https://doi.org/10.3904/kjim.2019.188.e1
  24. Hirano T. Pathophysiology of diabetic dyslipidemia. J Atheroscler Thromb 2018; 25(9): 771-782. https://doi.org/10.5551/jat.rv17023
  25. Jideonwo V, Hou Y, Ahn M, Surendran S, Morral N. Impact of silencing hepatic SREBP-1 on insulin signaling. PLoS One 2018; 13(5): e0196704. https://doi.org/10.1371/journal.pone.0196704
  26. Su W, Cao R, He YC, Guan YF, Ruan XZ. Crosstalk of hyperglycemia and dyslipidemia in diabetic kidney disease. Kidney Dis (Basel) 2017; 3(4): 171-180. https://doi.org/10.1159/000479874
  27. Cornier MA, Dabelea D, Hernandez TL, Lindstrom RC, Steig AJ, Stob NR, et al. The metabolic syndrome. Endocr Rev 2008; 29(7): 777-822. https://doi.org/10.1210/er.2008-0024
  28. Robins SJ, Lyass A, Zachariah JP, Massaro JM, Vasan RS. Insulin resistance and the relationship of a dyslipidemia to coronary heart disease: the Framingham Heart Study. Arterioscler Thromb Vasc Biol 2011; 31(5): 1208-1214. https://doi.org/10.1161/ATVBAHA.110.219055
  29. Vladu IM, Fortofoiu M, Clenciu D, Fortofoiu MC, Padureanu R, Radu L, et al. Insulin resistance quantified by the value of HOMA-IR and cardiovascular risk in patients with type 2 diabetes. Exp Ther Med 2022; 23(1): 73.
  30. Leslie RD, Cohen RM. Biologic variability in plasma glucose, hemoglobin A1c, and advanced glycation end products associated with diabetes complications. J Diabetes Sci Technol 2009; 3(4): 635-643. https://doi.org/10.1177/193229680900300403
  31. Kass DA, Shapiro EP, Kawaguchi M, Capriotti AR, Scuteri A, deGroof RC, et al. Improved arterial compliance by a novel advanced glycation end-product crosslink breaker. Circulation 2001; 104(13): 1464-1470. https://doi.org/10.1161/hc3801.097806
  32. Grindel A, Guggenberger B, Eichberger L, Poppelmeyer C, Gschaider M, Tosevska A, et al. Oxidative stress, DNA damage and DNA repair in Female patients with diabetes mellitus type 2. PLoS One 2016; 11(9): e0162082. https://doi.org/10.1371/journal.pone.0162082
  33. Otterbein LE, Choi AM. Heme oxygenase: colors of defense against cellular stress. Am J Physiol Lung Cell Mol Physiol 2000; 279(6): L1029-L1037. https://doi.org/10.1152/ajplung.2000.279.6.L1029
  34. Kirino Y, Takeno M, Iwasaki M, Ueda A, Ohno S, Shirai A, et al. Increased serum HO-1 in hemophagocytic syndrome and adult-onset Still's disease: use in the differential diagnosis of hyperferritinemia. Arthritis Res Ther 2005; 7(3): R616-R624. https://doi.org/10.1186/ar1721
  35. He M, Siow RC, Sugden D, Gao L, Cheng X, Mann GE. Induction of HO-1 and redox signaling in endothelial cells by advanced glycation end products: a role for Nrf2 in vascular protection in diabetes. Nutr Metab Cardiovasc Dis 2011;21(4): 277-285. https://doi.org/10.1016/j.numecd.2009.12.008